文献速递呼吸衰竭与机械通气心脑血管急症

利伐沙班用于急诊科肺栓塞早期出院的多中心试验(MERCURY PE):依据与设计

Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
PubMed 文献 · Acad Emerg Med · 2016-10-31
一句话结论MERCURY PE试验旨在验证:经Hestia标准筛选的低危肺栓塞成人患者,口服利伐沙班门诊治疗能否比标准治疗减少住院天数。

该文描述MERCURY PE随机对照试验的设计,旨在检验低危肺栓塞患者在家中使用利伐沙班可安全有效管理、住院天数少于标准治疗的假设。研究为多中心、开放标签、随机临床试验,低危成人肺栓塞患者(按Hestia标准识别)随机分为门诊口服利伐沙班15 mg每日两次共21天、随后20 mg每日一次共90天,或由治疗医师根据当地实践决定的标准治疗。主要临床终点为随机化后前30天内静脉血栓栓塞或出血相关事件的总住院天数(含指数住院)。每组150例受试者将提供82%把握度检出主要结局1天或以上的差异;目前入组正在进行,60个计划中心中45个已启动。

要点

  • 低危成人肺栓塞患者按Hestia标准识别,随机分为门诊利伐沙班治疗或标准治疗。
  • 利伐沙班方案:口服15 mg每日两次共21天,随后20 mg每日一次共90天。
  • 主要终点为随机化后前30天内静脉血栓栓塞或出血相关事件的总住院天数(含指数住院)。
  • 每组150例受试者提供82%把握度检出主要结局1天或以上的差异。
  • 入组正在进行,60个计划中心中45个已启动;未计划中期分析,由数据安全管理委员会监查。

适用人群与场景

  • 低危成人肺栓塞患者,由Hestia标准识别。

诊断标准与关键阈值

  • 低危肺栓塞采用Hestia标准识别。

处置流程与药物剂量

  • 门诊管理组:口服利伐沙班15 mg每日两次共21天,随后20 mg每日一次共90天。
  • 标准治疗组:由治疗医师根据当地实践决定。

研究设计与关键结果

  • 研究为多中心、开放标签、随机临床试验,低危成人肺栓塞患者随机分为门诊利伐沙班治疗或标准治疗。
  • 主要临床终点为随机化后前30天内静脉血栓栓塞或出血相关事件的总住院天数(含指数住院)。
  • 每组150例受试者将提供82%把握度检出主要结局1天或以上的差异。
  • 目前患者入组正在进行,60个计划中心中45个已启动。
  • 未计划中期分析,研究由数据安全管理委员会监查。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机对照试验的设计文章。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该设计文章未报告结果,原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Traditionally, patients with pulmonary embolism (PE) are admitted from the emergency department and treated with low-molecular-weight heparin followed by warfarin. Several studies now demonstrate that it is possible to identify low-risk PE patients that can safely be treated as outpatients. The advent of the direct-acting oral anticoagulants such as rivaroxaban has made it easier than ever to manage patients outside of the hospital. This article describes the design of a randomized controlled trial aimed at testing the hypothesis that low-risk PE patients can be safely and effectively managed at home using rivaroxaban, resulting in fewer days of hospitalization than standard-of-care treatment.

METHODS: We have initiated a multicenter, open-label, randomized clinical trial in which low-risk adult PE patients (identified by the Hestia criteria) are randomized to outpatient management with oral rivaroxaban 15 mg twice daily for 21 days followed by 20 mg once daily for 90 days versus standard care, determined by the treating physician and based on local practices. The primary clinical endpoint will be the total number of inpatient hospital days (including the index admission) for venous thromboembolic or bleeding-related events during the first 30 days after randomization. A total of 150 subjects per group will provide 82% power to detect a difference of 1 day or greater in the primary outcome.

RESULTS: Patient enrollment is ongoing at present in 45 of 60 planned sites. No interim analysis is planned and the study is being monitored by a data safety management board.

CONCLUSIONS: The MERCURY PE study is designed to test the hypothesis that outpatient management of low-risk PE patients with rivaroxaban reduces the number of hospitalization days from venous thromboembolism and bleeding compared with standard care. This article describes the rationale and methodology for this study.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Singer AJ, Xiang J, Kabrhel C, et al. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Acad Emerg Med. 2016. PMID: 27537530. doi:10.1111/acem.13072

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。